Simplified Chinese
scroll down
11
2024-05
On May 10, 2024, Liu Xueliang, Deputy Secretary of the CPC Daxing District Committee and District Mayor of Beijing, led a delegation to visit and conduct an on-site inspection of Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as Minhai Bio), gaining an in-depth understanding of the development status of key enterprises and industry benchmarks in Daxing District. Joining the visit were Wu Hao, Deputy District Mayor; Zhang Bin, Director of the District Government Office; Tang Shengming, Director of the District Bureau of Statistics; Ma Yanzhu, Director of the District Industrial Promotion Center; and Zhang Liqun, Party Secretary and Chairman of the Biomedical Base, among other leaders. Accompanying the delegation were Liu Jiankai, Executive Deputy General Manager, and Li Guanghui, Deputy General Manager, of Minhai Bio. The delegation, led by Liu Xueliang, conducted field visits and…
27
2024-03
Zheng Haifa: Bringing China’s Vaccines to the World
Zheng Haifa, male, born in October 1964 in Tonghua, Jilin Province, holds a master’s degree in wildlife science from the Chinese Academy of Agricultural Sciences and is a senior engineer. He currently serves as the General Manager of Beijing Minhai Biotechnology Co., Ltd. With extensive experience in vaccine technology research, development, and management, he is a technical reviewer for national programs such as the “863 Program” and the “Major New Drug Development” initiative. He has led the development of acellular DPT‑b type influenza vaccine and lyophilized human rabies vaccine, achieving significant economic and social benefits. He established the R&D Center of Beijing Minhai Biotechnology Co., Ltd. and, as project leader, spearheaded the construction of an innovation capacity‑building project for the Beijing Municipal Engineering Laboratory on novel vaccines.
05
2024-01
Recently, the National Intellectual Property Administration issued the “Notice of the National Intellectual Property Administration on Designating the New Batch of 2023 and the Re‑certified National Intellectual Property Demonstration Enterprises and Advantageous Enterprises.” Beijing Minhai Biotechnology Co., Ltd. has been recognized as a “National Intellectual Property Demonstration Enterprise.” Image source: Official website of the National Intellectual Property Administration. A National Intellectual Property Demonstration Enterprise is an enterprise that embodies a strategic approach to intellectual property management, demonstrates well‑rounded capabilities in IP creation, utilization, protection, and administration, possesses distinct comprehensive competitive advantages in the field, and serves as a benchmark with significant industry influence. This designation represents the highest honor the state confers for outstanding IP management practices.
20
2023-12
On December 11, 2023, Beijing Minhai Biotechnology Co., Ltd., a wholly owned subsidiary of Kangtai Biological, signed the “License and Technology Transfer Agreement for the 13‑Valent Pneumococcal Polysaccharide Conjugate Vaccine” with the Egyptian vaccine company Gennvax Egypt. The two parties have entered into a commercial partnership to grant licensing and transfer technology for Minhai Biotechnology’s independently developed and manufactured world’s first dual‑carrier 13‑valent pneumococcal polysaccharide conjugate vaccine, jointly advancing the approval and market launch of the finished vaccine in Egypt, as well as local bulk‑fill and finish operations. The signing ceremony was held ceremoniously at the Beijing Minhai International New‑Type Vaccine Internationalization Industrial Base, attended by Minhai’s general manager.
15
2023-11
On November 14, 2023, a delegation led by Hao Zehong, member of the Party Leadership Group and Vice Chairman of the Daxing District Federation of Trade Unions, along with Han Fengguang, head of the Rights and Interests Department of the Daxing District Federation of Trade Unions, paid a visit to Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as Minhai Bio) to conduct a supervisory inspection as part of the special initiative to promote amendments to the “Beijing Municipal Collective Contract Regulations.” Members of the collective bargaining guidance team and relevant officials from the trade union of the biopharmaceutical industrial base also attended the inspection. Wang Hui, Assistant General Manager of Minhai Bio, Zhang Ning, Deputy Manager of the Human Resources Department, Ma Hongjuan, Vice Chairwoman of the trade union, and other related personnel accompanied the delegation. Assistant General Manager Wang Hui briefed the inspection team on Minhai Bio’s efforts regarding collective bargaining…
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account
0
%